<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515722</url>
  </required_header>
  <id_info>
    <org_study_id>2010-05-106</org_study_id>
    <nct_id>NCT01515722</nct_id>
  </id_info>
  <brief_title>Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder</brief_title>
  <official_title>Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder : 6-month, Randomized, Open-label, Multi-center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objectives: To explore the effectiveness of adjunctive intervention to enhance the&#xD;
      medication compliance and persistence in patients with Overactive Bladder (OAB), thereby to&#xD;
      improve treatment outcomes&#xD;
&#xD;
      Study Hypothesis: Health Education Intervention (HEI) can enhance the medication compliance&#xD;
      and persistence, thereby can improve the treatment outcomes in conjunction with&#xD;
      pharmacological therapy in OAB patients&#xD;
&#xD;
      Study Design: 6-month, randomized, open-label, multi-center trial at 13 university hospitals&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment - Fesoterodine (Toviaz) 4 or 8mg&#xD;
&#xD;
      Interventions (2 arms)&#xD;
&#xD;
      - Arm 1: No intervention&#xD;
&#xD;
      Patients in this arm will not be given HEI in conjunction with pharmacotherapy (Toviaz) which&#xD;
      was developed for this trial.&#xD;
&#xD;
      - Arm 2: Health education intervention (HEI)&#xD;
&#xD;
      HEI will be performed by trained study coordinators with the leaflet designed for this trial&#xD;
      composed of 4 parts.&#xD;
&#xD;
        1. Part 1: Understanding OAB Physiology of bladder Definition, symptom and prevalence of&#xD;
           OAB OAB in a treatable condition. There are many options that may help your symptoms.&#xD;
           Lifestyle change Medications Bladder training Pelvic floor muscle exercise&#xD;
&#xD;
        2. Part 2: Behavioral/lifestyle modification Modification of dietary habits Limit bladder&#xD;
           irritants- caffeine (coffee, tea, coke...), juice, chemical flavors, spicy food. etc.&#xD;
           Altering fluid intake Weight management Learn how weight can affect their condition Stop&#xD;
           smoking Constipation management&#xD;
&#xD;
        3. Part 3: Bladder training Timed voiding- Goal is urinating every 3 or 4 hours during the&#xD;
           day without fear of wetting accidents.&#xD;
&#xD;
           Urgency suppression Pelvic muscle contraction, count backwards from 100 by 7seconds, etc&#xD;
           Pelvic floor muscle exercise Contraction (fast and slow) and relax the muscle for a&#xD;
           count of 3. Repeat the fast and slow contractions 10 - 15 times. Do those at least 3&#xD;
           times a day.&#xD;
&#xD;
        4. Part 4: Understanding antimuscarinics How the medicine works How to take it Tips that&#xD;
           may help manage side effects- dry mouth, constipation Therapy expectations&#xD;
&#xD;
        5. HEI include 3-day voiding diary for self tracking method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the % of patients maintaining persistence between no intervention and HEI group</measure>
    <time_frame>6 months</time_frame>
    <description>Definition of &quot;Maintaining Persistence&quot;= a gap of ≤ 30 days between successive prescription fills</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in the % of patients maintaining persistence between no intervention and HEI group</measure>
    <time_frame>1, 2 and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the % of the patients with the compliance rate ≥ 80% between no intervention and HEI group</measure>
    <time_frame>1, 2, 4, and 6 months</time_frame>
    <description>Calculation of Compliance (%)= (total no. of drug prescribed - no. of remained drug)/total no. of drug prescribed x 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the compliance rate between no intervention and HEI group</measure>
    <time_frame>1, 2, 4 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in OAB symptoms between no intervention and HEI group</measure>
    <time_frame>1, 2, 4, and 6 months</time_frame>
    <description>OABSS OAB-q short form questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the treatment satisfaction between no intervention and HEI group</measure>
    <time_frame>1, 2, 4, and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for non-persistence</measure>
    <time_frame>1, 2, 4, and 6 months</time_frame>
    <description>Definition of non-persistence = a gap of &gt; 30 days between successive prescription fills&#xD;
Examples&#xD;
Insufficient clinical response&#xD;
Adverse event&#xD;
Satisfied with treatment response&#xD;
Laboratory abnormality&#xD;
Subject died&#xD;
Protocol violation&#xD;
Lost to F/U&#xD;
Subject no longer willing to participate in study&#xD;
Pregnancy&#xD;
High patient out-pocket cost&#xD;
Others (provide detailed reason)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1, 2, 4, and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">692</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Health education intervention (HEI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Health education intervention (HEI)</intervention_name>
    <description>&lt;Part 1&gt; Understanding OAB&#xD;
&lt;Part 2&gt; Behavioral/lifestyle modification&#xD;
&lt;Part 3&gt; Bladder training&#xD;
&lt;Part 4&gt; Understanding antimuscarinics</description>
    <arm_group_label>Health education intervention (HEI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female aged ≥ 18 years with OAB symptoms for ≥ 3 months&#xD;
&#xD;
          -  The sum score of the OABSS ≥ 3 with the score of the question no.3 (urgency) ≥ 2&#xD;
&#xD;
          -  The sum score of the OAB V8 ≥ 8&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition that would contraindication of anticholinergic treatment&#xD;
&#xD;
          -  Symptomatic acute UTI during the run-in period&#xD;
&#xD;
          -  Diagnosed or suspected interstitial cystitis&#xD;
&#xD;
          -  Treatment with anticholinergic drugs within 12 months prior to Screening and persist&#xD;
             over 3 months&#xD;
&#xD;
          -  Treatment within the 14 days preceding Screening, or expected to initiate treatment&#xD;
             during the study with any other treatment for overactive bladder.&#xD;
&#xD;
          -  An indwelling catheter or practicing intermittent self-catheterization&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu-Sung Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bucheon St. Mary's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Bucheon</city>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bucheon Hospital, Soonchunhyang University College of Medicine</name>
      <address>
        <city>Bucheon</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Changwon Hospital, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Changwon</city>
        <zip>630-522</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University College of Medicine</name>
      <address>
        <city>Daegu</city>
        <zip>705-034</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Medical School</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheil General Hospital &amp; Women's Healthcare Center, College of Medicine, Kwandong University</name>
      <address>
        <city>Seoul</city>
        <zip>100-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anam Hospital, College of Medicine, Korea University</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center, Ulsan University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>July 22, 2011</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medication Persistence</keyword>
  <keyword>Compliance</keyword>
  <keyword>Health Education Intervention (HEI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

